Singapore markets closed

Avacta Group Plc (RTQ1.F)

Frankfurt - Frankfurt Delayed Price. Currency in EUR
Add to watchlist
1.4500+0.2300 (+18.85%)
As of 8:04AM CEST. Market open.
Full screen
Previous close1.2200
Open1.4500
Bid1.3800 x N/A
Ask1.4400 x N/A
Day's range1.4500 - 1.4500
52-week range1.1150 - 3.2200
Volume1,020
Avg. volume112
Market cap372.037M
Beta (5Y monthly)2.15
PE ratio (TTM)N/A
EPS (TTM)-0.0980
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Business Wire

    Avacta Announces First Patient Dosed in AVA6000 Pro-Doxorubicin Phase I Clinical Trial

    CAMBRIDGE & WETHERBY, England, August 11, 2021--Avacta Group plc (AIM: AVCT), a clinical stage biopharmaceutical company developing innovative cancer therapies and powerful diagnostics based on its proprietary Affimer® and pre|CISION™ platforms, is pleased to announce that the first patient has been dosed in its Phase I multicentre trial evaluating AVA6000, a novel pro-drug of Doxorubicin.

  • Business Wire

    Avacta’s Diagnostic Division Achieves ISO 13485 Certification

    CAMBRIDGE, England & WETHERBY, England, July 14, 2021--Avacta Group plc (AIM: AVCT), the developer of diagnostics and innovative cancer therapies based on its proprietary Affimer® and pre|CISION™ platforms, is pleased to announce that Avacta Life Sciences’ diagnostics division has achieved ISO 13485 certification for the quality management system for the manufacture and distribution of Affimer reagents for use in lateral flow, ELISA and immunodiagnostic in-vitro diagnostic devices.

  • Business Wire

    Avacta Announces AffiDX® SARS-CoV-2 Antigen Lateral Flow Test Detects Delta Variant

    CAMBRIDGE, AND WETHERBY, UK, June 29, 2021--Avacta Group plc (AIM: AVCT), the developer of diagnostics and innovative cancer therapies based on its proprietary Affimer® and pre|CISION™ platforms, is pleased to announce that a study has shown that the AffiDX antigen lateral flow test detects the Delta variant of the SARS-CoV-2 virus in clinical samples and, in this small study, outperformed two lateral flow antigen tests that are commercially available in Europe.